To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center clinical study to evaluate the efficacy and safety of XNW5004 tablets in subjects with R/R PTCL. The study plans to enroll approximately 50 subjects.